Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch

Benzinga14:56 ET

Apellis Pharmaceuticals Analyst Ratings

BenzingaOct 16 09:57 ET · Ratings

Scotiabank Initiates Apellis Pharmaceuticals at Sector Perform With $35 Price Target

MT NewswiresOct 16 08:11 ET · Ratings

Express News | Apellis Pharmaceuticals Inc : William Blair Initiates Coverage With Outperform Rating; Fair Value Estimate $50

ReutersOct 16 07:06 ET

Express News | Apellis Announces Oral Presentation at American Society of Nephrology (Asn) Kidney Week on Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary Ic-Mpgn

ReutersOct 16 07:00 ET

Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

GlobeNewswireOct 16 07:00 ET